The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutic Pipeline Program, 2021Harnessing the ADAR Protein to Repair the LRRK2 Mutation Causing Parkinson's Disease
Study Rationale:
The majority of cases of inherited Parkinson’s disease (PD) are caused by a single-letter change in the gene that encodes the LRRK2 protein. The mutation, which changes a G to an... -
Therapeutic Pipeline Program, 2021Evaluating the Safety, Tolerability and Potential Efficacy of SB-0107 for Treating Parkinson’s Disease and Levodopa-Induced Dyskinesia
Study Rationale:
Although levodopa is an effective treatment for Parkinson’s disease (PD), its ability to activate dopamine D1 receptors also leads to its most vexing side effect: dyskinesia. An... -
Therapeutic Pipeline Program, 2021Using Ketamine to Treat Depression in Parkinson’s Disease
Study Rationale:
Depression affects around half of people with Parkinson’s disease (PD). However, existing antidepressants are not effective in treating these symptoms in PD and new treatments are... -
Analysis of Patient-Reported Outcomes from Fox Insight, 2021Overcoming Underrepresentation to Improve Generalizability in Fox Insight
Study Rationale:
Fox Insight is an online clinical study that surveys over 25,000 people with Parkinson disease (PD) about their overall health, symptoms and well-being. Unfortunately, certain groups... -
Therapeutic Pipeline Program, 2021Targeting Brain-specific Stearoyl-CoA-Desaturase 5 (SCD5) as a Treatment for Parkinson’s Disease
Study Rationale:
Previous studies have shown that fat molecules called unsaturated fatty acids regulate the harmful effects that alpha-synuclein have on neurons. This protein forms a key part of Lewy... -
Therapeutic Pipeline Program, 2021Assessing the Potential of Low-Dose Carbon Monoxide Therapy in Parkinson’s Disease
Study Rationale:
Although carbon monoxide (CO) is commonly considered harmful, a growing body of research suggests that low doses of CO can stimulate physiologic processes that may protect against...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.